Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
721 to 740 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Anti-SARS-CoV-1 and -2 nanobody engineering towards avidity-inspired therapeutics. | Nano Today | 2022 | 34840592 | PubTator, text mining | PubMed |
| Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. | Cancer Rep (Hoboken) | 2022 | 34821081 | PubTator, text mining | PubMed |
| SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds? | Clin Lymphoma Myeloma Leuk | 2022 | 34774461 | PubTator, text mining | PubMed |
| Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall. | Hum Pathol | 2022 | 34767860 | PubTator, text mining | PubMed |
| Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland. | Eur J Health Econ | 2022 | 34757508 | PubTator, text mining | PubMed |
| Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. | Am J Hematol | 2022 | 34699616 | PubTator, text mining | PubMed |
| Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. | Blood | 2022 | 34699592 | PubTator, text mining | PubMed |
| Transcriptome and unique cytokine microenvironment of Castleman disease. | Mod Pathol | 2022 | 34686774 | PubTator, text mining | PubMed |
| Chronic lymphocytic leukemia in China. | Chin Med J (Engl) | 2022 | 34636775 | PubTator, text mining | PubMed |
| Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. | Blood Adv | 2022 | 34614513 | PubTator, text mining | PubMed |
| The cure of leukemia through the optimist's prism. | Cancer | 2022 | 34614211 | PubTator, text mining | PubMed |
| Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4. | Intern Med | 2022 | 34544945 | PubTator, text mining | PubMed |
| Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients. | Leukemia | 2022 | 34417556 | PubTator, text mining | PubMed |
| Comparison of clinical pharmacogenetic recommendations across therapeutic areas. | Pharmacogenet Genomics | 2022 | 34412102 | PubTator, text mining | PubMed |
| Immunity to SARS-CoV-2 induced by infection or vaccination. | J Intern Med | 2022 | 34352148 | PubTator, text mining | PubMed |
| Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia. | Cancer Rep (Hoboken) | 2022 | 34250757 | PubTator, text mining | PubMed |
| Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. | Leukemia | 2022 | 34148055 | PubTator, text mining | PubMed |
| Smudge cells percentage on blood smear is a reliable prognostic marker in chronic lymphocytic leukemia. | Hematol Transfus Cell Ther | 2022 | 34116931 | PubTator, text mining | PubMed |
| IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load. | Haematologica | 2022 | 34092057 | PubTator, text mining | PubMed |
| The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. | Haematologica | 2022 | 34092056 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=37